Shanghai Allist Pharmaceuticals Co., Ltd. (SHA:688578)
China
· Delayed Price · Currency is CNY 90.59
+1.83 (2.06%)
Apr 2, 2025, 1:45 PM CST
SHA:688578 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2017 |
| Operating Revenue | 3,558 | 2,018 | 790.94 | 530.08 | 0.55 | Upgrade
|
| Other Revenue | - | 0.06 | 0.06 | 0.02 | 0.02 | Upgrade
|
| Revenue | 3,558 | 2,018 | 791 | 530.09 | 0.56 | Upgrade
|
| Revenue Growth (YoY) | 76.29% | 155.14% | 49.22% | 94409.97% | -10.93% | Upgrade
|
| Cost of Revenue | - | 110.02 | 47.11 | 29.95 | 0.16 | Upgrade
|
| Gross Profit | 3,558 | 1,908 | 743.9 | 500.14 | 0.4 | Upgrade
|
| Selling, General & Admin | - | 1,052 | 524.11 | 366.44 | 185.12 | Upgrade
|
| Research & Development | - | 280.92 | 175.71 | 200.61 | 175.42 | Upgrade
|
| Other Operating Expenses | 1,925 | 26.6 | 5.11 | 2.79 | 1.64 | Upgrade
|
| Operating Expenses | 1,925 | 1,359 | 705.26 | 569.95 | 362.16 | Upgrade
|
| Operating Income | 1,633 | 549.56 | 38.64 | -69.81 | -361.76 | Upgrade
|
| Interest Expense | - | -0.16 | -0.33 | -0.61 | -1.14 | Upgrade
|
| Interest & Investment Income | - | 60.19 | 33.06 | 30.06 | 21.4 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 4.35 | 17.17 | -3.38 | -0.35 | Upgrade
|
| Other Non Operating Income (Expenses) | -16.23 | -0.26 | -1.06 | -0.43 | -0.1 | Upgrade
|
| EBT Excluding Unusual Items | 1,617 | 613.68 | 87.47 | -44.16 | -341.96 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 22.67 | 32.36 | 48.13 | 8.3 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.02 | -1.68 | -0.57 | - | Upgrade
|
| Asset Writedown | - | - | - | - | -0.02 | Upgrade
|
| Other Unusual Items | - | 19.89 | 7.85 | 14.88 | 23.16 | Upgrade
|
| Pretax Income | 1,617 | 656.22 | 126 | 18.27 | -310.52 | Upgrade
|
| Income Tax Expense | 192.91 | 12.05 | -4.52 | - | - | Upgrade
|
| Net Income | 1,424 | 644.17 | 130.52 | 18.27 | -310.52 | Upgrade
|
| Net Income to Common | 1,424 | 644.17 | 130.52 | 18.27 | -310.52 | Upgrade
|
| Net Income Growth | 121.08% | 393.54% | 614.22% | - | - | Upgrade
|
| Shares Outstanding (Basic) | 451 | 450 | 450 | 457 | 370 | Upgrade
|
| Shares Outstanding (Diluted) | 451 | 450 | 450 | 457 | 370 | Upgrade
|
| Shares Change (YoY) | 0.04% | 0.09% | -1.49% | 23.59% | 2.30% | Upgrade
|
| EPS (Basic) | 3.16 | 1.43 | 0.29 | 0.04 | -0.84 | Upgrade
|
| EPS (Diluted) | 3.16 | 1.43 | 0.29 | 0.04 | -0.84 | Upgrade
|
| EPS Growth | 120.98% | 393.10% | 625.00% | - | - | Upgrade
|
| Free Cash Flow | - | 606.77 | -52.21 | -162.95 | -285.2 | Upgrade
|
| Free Cash Flow Per Share | - | 1.35 | -0.12 | -0.36 | -0.77 | Upgrade
|
| Dividend Per Share | - | 0.400 | - | - | - | Upgrade
|
| Gross Margin | 100.00% | 94.55% | 94.05% | 94.35% | 71.17% | Upgrade
|
| Operating Margin | 45.91% | 27.23% | 4.88% | -13.17% | -64498.21% | Upgrade
|
| Profit Margin | 40.03% | 31.92% | 16.50% | 3.45% | -55361.45% | Upgrade
|
| Free Cash Flow Margin | - | 30.06% | -6.60% | -30.74% | -50847.96% | Upgrade
|
| EBITDA | 1,670 | 586.5 | 58.8 | -56 | -349.9 | Upgrade
|
| EBITDA Margin | 46.95% | 29.06% | 7.43% | -10.56% | - | Upgrade
|
| D&A For EBITDA | 36.94 | 36.94 | 20.16 | 13.81 | 11.86 | Upgrade
|
| EBIT | 1,633 | 549.56 | 38.64 | -69.81 | -361.76 | Upgrade
|
| EBIT Margin | 45.91% | 27.23% | 4.88% | -13.17% | - | Upgrade
|
| Effective Tax Rate | 11.93% | 1.84% | - | - | - | Upgrade
|
| Revenue as Reported | - | 2,018 | 791 | 530.09 | 0.56 | Upgrade
|
| Advertising Expenses | - | 552.06 | 201.38 | 22.44 | 0.47 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.